Trial Profile
National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors UCB
- 15 Jul 2020 Status changed from recruiting to completed.
- 11 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Aug 2019.
- 15 Oct 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.